Trevi Therapeutics Inc (Nasdaq: TRVI), a US-based clinical-stage biopharmaceutical company, announced on Tuesday that it has named Margaret Garin, MD, MSCR, as its new vice president of Clinical Development.
In the new role, Dr Garin will be responsible for advancing the clinical development of the company's Haduvio in chronic cough.
Dr Garin has more than 14 years of industry and academic research experience and more than nine years of global pharmaceutical industry experience in early and late-stage development. She has served as the executive director of Clinical Development at Bellus Health (now owned by GSK). She was the clinical development lead for programs in respiratory and inflammation at Teva Pharmaceuticals.
AstraZeneca secures EU recommendation for Imfinzi in limited-stage small cell lung cancer
hVIVO to conduct RSV human challenge trial for Inhalon Biopharma
Alvogen recalls one lot of Fentanyl transdermal patches
ImmunityBio partners with BeiGene for Phase 3 NSCLC trial of ANKTIVA and PD-1 inhibitor
ANGLE plc reports successful dual CTC-DNA and ctDNA analysis using Illumina platform
Median Technologies secures funding for eyonis Lung Cancer Screening software
Genprex commences Phase 2 expansion of Acclaim-3 clinical study in ES-SCLC
Novocure opens new global headquarters in Baar, Switzerland
Vast Therapeutics receives USD2m grant from National Institutes of Health
Nanobiotix reports first patient dosed in Phase 2 lung cancer study
AstraZeneca's Datroway approved in US for HR-positive breast cancer
Innovent and ASK Pharm's limertinib NDA receives Chinese regulatory approval
RYBREVANT approved in Canada for second-line EGFR-mutated lung cancer
OS Therapies reports positive Phase 2b data for OST-HER2 in lung metastatic osteosarcoma